Zydus Medtech and Braile Biomedica of Brazil announce global licensing pact to commercialize TAVI technology

Zydus MedTech Private Limited, a subsidiary of Zydus Lifesciences Limited, has entered into a strategic partnership with Braile Biomédica Industria, Comércio e¢ Representagdes Ltda. to exclusively commercialize its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets. This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment. The global TAVI market, currently valued at over USD 6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures. Zydus MedTech will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica will manufacture and supply the product for these markets, with Zydus MedTech retaining rights to manufacture select components of the TAVI system. This collaboration provides operational flexibility while laying the foundation for further product innovation and development. The TAVI procedure is a recognized breakthrough in structural heart care, particularly for elderly patients or those at high surgical risk. The system was developed based on the doctoral thesis of Dr. Domingo Braile, a pioneer of cardiac surgery in Brazil, and features a unique bovine pericardium sheet, ensuring exceptional biocompatibility, durability, and performance.